Reaction
Metastatic Malignant Melanoma reporting signals
As of the last recalculation, Metastatic Malignant Melanoma appears in 2,265 FAERS reports alongside 28 co-occurring drug terms. The strongest observed disproportionality signal is DABRAFENIB (PRR 262.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Dabrafenib | 476 | 262.6 | 268.7 |
| Trametinib | 486 | 235.0 | 239.9 |
| Vemurafenib | 102 | 81.6 | 82.3 |
| Encorafenib | 37 | 34.9 | 35.0 |
| Ipilimumab | 149 | 33.9 | 34.0 |
| Nivolumab | 174 | 17.8 | 17.9 |
| Anti-Thymocyte Globulin (Rabbit) | 15 | 17.2 | 17.2 |
| Temozolomide | 38 | 16.8 | 16.9 |
| Thalidomide | 65 | 16.7 | 16.7 |
| Dalteparin Sodium | 15 | 13.1 | 13.1 |
| Pembrolizumab | 135 | 12.5 | 12.5 |
| Mycophenilic Acid | 21 | 9.4 | 9.4 |
| Sildenafil Citrate | 119 | 9.0 | 9.0 |
| Sirolimus | 13 | 8.9 | 8.9 |
| Moxifloxacin Hydrochloride | 19 | 8.7 | 8.7 |
| Durvalumab | 18 | 8.2 | 8.2 |
| Basiliximab | 9 | 7.1 | 7.1 |
| Fludarabine Phosphate | 29 | 6.9 | 6.9 |
| Tadalafil | 72 | 6.8 | 6.8 |
| Mycophenolic Acid | 21 | 6.1 | 6.1 |
| Lapatinib | 9 | 5.3 | 5.4 |
| Levetiracetam In Sodium Chloride | 39 | 4.7 | 4.7 |
| Levetiracetam Oral | 39 | 4.7 | 4.7 |
| Levetiracetam Injection | 39 | 4.7 | 4.7 |
| Imatinib Mesylate | 13 | 4.3 | 4.3 |
| Vismodegib | 4 | 4.1 | 4.1 |
| Polatuzumab Vedotin | 4 | 3.8 | 3.8 |
| Paclitaxel | 36 | 3.4 | 3.4 |